Cortes et al. reported the preliminary results of a phase I/II clinical trial involving the treatment of 20 IDH1-mutant MDS patients with olutasidenib alone or in combination with azacitidine; clinical responses were observed in 33% of patients treated with monotherapy and in 73% of patients treated with combination therapy [153]. Here, IDH1 is linked to myelodysplastic syndrome.